Completed PHASE1 INTERVENTIONAL 4-arm NCT02924337

Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects

A Randomised, Double-blind, Placebo and Active Controlled Crossover Study to Assess the Effect of Single Dose Administration of 2 Doses of Imeglimin on QT/QTc Intervals in Healthy Subjects

Sponsor: Poxel SA

Conditions Qt Interval, Variation in

Interventions Imeglimin Moxifloxacin Placebo

Updated 6 times since 2017 Last updated: Feb 9, 2017 Started: Sep 30, 2016 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Qt Interval, Variation in and is currently completed. Poxel SA leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Poxel SA

Data source: Poxel SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom